← back to search

Christine N. Spencer

Parker Institute for Cancer Immunotherapy · US
Area of research
Immunology · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Immune cells in cancer, and Gut microbiota and health.
h-index
17
citations
7,670
works
240
NIH funding
primary concept
Medicine
email

Recent publications

Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Journal for ImmunoTherapy of Cancer 2025cited by 17position: middledoi
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study
Journal for ImmunoTherapy of Cancer 2025cited by 13position: middledoi
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
Cancer Discovery 2024cited by 64position: middledoi
Canadian high arctic ice core records of organophosphate flame retardants and plasticizers
Environmental Science Processes & Impacts 2023cited by 8position: middledoi
Hallmarks of Resistance to Immune-Checkpoint Inhibitors
Cancer Immunology Research 2022cited by 129position: middledoi
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Journal for ImmunoTherapy of Cancer 2022cited by 45position: middledoi
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Clinical Cancer Research 2022cited by 34position: middledoi
508 Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition
Regular and Young Investigator Award Abstracts 2022cited by 1position: middledoi
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Science 2021cited by 859position: firstdoi
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Nature Medicine 2021cited by 405position: middledoi
B cells and tertiary lymphoid structures promote immunotherapy response
Nature 2020cited by 2,612position: middledoi
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Research Square 2020cited by 11position: middledoi
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
The Lancet Oncology 2018cited by 655position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Daniel K. Wells · Parker Institute for Cancer Immunotherapy3 papers (2022–2022)Lisa H. Butterfield · University of San Francisco2 papers (2022–2025)Alexandria P. Cogdill · Immunai (United States)2 papers (2022–2022)Christian Hammer · Altos Labs2 papers (2022–2025)Erik Wennerberg · Institute of Cancer Research2 papers (2022–2022)Cara Haymaker · The University of Texas MD Anderson Cancer Center2 papers (2022–2022)Alessandra Cesano · Seattle University2 papers (2022–2025)Heather M. McGee · City Of Hope National Medical Center2 papers (2022–2022)Yana G. Najjar · UPMC Hillman Cancer Center2 papers (2022–2025)Samantha Bucktrout · OBS Medical (United Kingdom)2 papers (2022–2025)Theresa LaVallee · Coherus BioSciences (United States)2 papers (2022–2022)Roberta Zappasodi · Cornell University2 papers (2022–2022)Randy F. Sweis · University of Illinois Chicago2 papers (2022–2022)Nils-Petter Rudqvist · Io Therapeutics (United States)2 papers (2022–2022)Anne Monette · McGill University Health Centre2 papers (2022–2022)Benjamin G. Vincent · University of North Carolina at Chapel Hill2 papers (2022–2022)Samantha I. Liang · Parker Institute for Cancer Immunotherapy1 papers (2025–2025)Igor Lehnherr · University of Waterloo1 papers (2023–2023)Sara Valpione · University of Manchester1 papers (2022–2022)Kevan C. Herold · Yale New Haven Hospital1 papers (2025–2025)